10 Best Diabetes Stocks To Buy According to Billionaires

2. Eli Lilly and Company (NYSE:LLY)

Number of Billionaires: 23

Dollar Value of Billionaire Holdings: $13,742,938,229

Eli Lilly and Company (NYSE:LLY) is a global leader in pharmaceuticals, specializing in diabetes care. Since introducing the world’s first commercial insulin in 1923, the company has maintained its position at the forefront of diabetes treatment. The company’s diabetes portfolio includes key products like Humalog (insulin lispro), Trulicity (dulaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide). These treatments address both type 2 diabetes and obesity.

Eli Lilly and Company (NYSE:LLY)’s Q4 2024 financial results reflect strong growth and innovation across the board. Their full-year revenue rose by 32%, with Q4 revenue jumping 45%, surpassing initial guidance by $4 billion. A major driver of this growth was the success of new products like Mounjaro for diabetes and Zepbound for weight loss, which together contributed over $3.1 billion in Q4 revenue. Mounjaro’s global sales reached $3.5 billion, while Zepbound generated $1.9 billion in the U.S.

The company’s profitability surged as well, with gross margins increasing to 83.2% and operating income more than doubling to $5.6 billion. EPS also saw a significant boost, rising to $5.32 from $2.49 in Q4 2023. Eli Lilly and Company (NYSE:LLY) experienced broad global growth, with notable increases in the U.S. (40%), Europe (82%), Japan (27%), and China (13%). Looking ahead, potential label expansions for Zepbound, including coverage for obstructive sleep apnea and heart failure, could further broaden the drug’s market potential.